Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 03 Aug 2022
FDA approves Coherus’ Cimerli (ranibizumab-eqrn) as the first and only interchangeable biosimilar to Lucentis for all five indications, with 12 months of interchangeability exclusivity
2 August 2022 - First Cimerli product sales expected in October 2022. ...
Posted by Michael Wonder on 03 Aug 2022
PHARMAC tells MPs medicine buying agency undergoing 'substantial change'
3 August 2022 - PHARMAC has undergone “substantial change” in the past few years, even before a hard hitting review ...
Posted by Michael Wonder on 03 Aug 2022
Bupa, Ramsay fight puts pressure on customers and Health Minister Mark Butler
3 August 2022 - Mark Butler finds himself in an uncomfortable position after Australia’s biggest private hospital operator Ramsay terminated ...
Posted by Michael Wonder on 03 Aug 2022
COVID-19 vaccines undergoing evaluation (3 August 2022)
3 August 2022 - The TGA has published a list (table) of the COVID-19 vaccines currently under evaluation by the agency. ...
Posted by Michael Wonder on 03 Aug 2022
Pralsetinib for treating advanced RET fusion positive non-small-cell lung cancer
3 August 2022 - NICE has published evidence-based recommendations on the use of pralsetinib (Gavreto) for the treatment of adults ...
Posted by Michael Wonder on 03 Aug 2022
TGA commences evaluation of Pfizer's COVID-19 vaccine (Comirnaty) for children aged 6 months to less than 5 years
3 August 2022 - The TGA has commenced evaluation of an application from Pfizer to extend the use of its ...
Posted by Michael Wonder on 02 Aug 2022
Patient reported outcome measures in clinical research
2 August 2022 - Health conditions may cause patients to feel ill and have impaired functioning in their daily lives. Thus, ...
Posted by Michael Wonder on 02 Aug 2022
Critics decry drug pricing provisions in Inflation Reduction Act, say they will stifle innovation
2 August 2022 - The push back against the prescription drug pricing provisions in the Inflation Reduction Act is relentless and ...
Posted by Michael Wonder on 02 Aug 2022
Marius Pharmaceuticals receives FDA approval of Kyzatrex, an oral testosterone replacement therapy
2 August 2022 - Marius Pharmaceuticals today announced the approval of Kyzatrex (testosterone undecanoate) by the U.S. FDA. ...
Posted by Michael Wonder on 02 Aug 2022
FDA official: patients play an increasing role in rare disease drug development
1 August 2022 - Patients have a critical role in drug development, from identifying unmet medical needs to assessing meaningful ...
Posted by Michael Wonder on 02 Aug 2022
Novo Nordisk receives FDA approval for Rebinyn for routine prophylaxis to prevent bleeding in people living with haemophilia B
29 July 2022 - Novo Nordisk announced today that the US FDA has approved the supplemental biologics license application for Rebinyn, ...
Posted by Michael Wonder on 02 Aug 2022
PHARMAC scrutiny a win for transparency
2 August 2022 - “PHARMAC’s appearance before the Health Select Committee tomorrow morning is a triumph for transparency and the ...
Posted by Michael Wonder on 02 Aug 2022
Delay of Evrysdi reimbursement review denies SMA patients' right to drug choice
2 August 2022 - The Government has been dragging its feet to review insurance benefits for Roche's new spinal muscular ...
Posted by Michael Wonder on 02 Aug 2022
Korea's first gene treatment for SMA Zolgensma gets insurance benefits
2 August 2022 - Novartis Korea said Monday that it released Zolgensma, the nation's first gene replacement treatment for spinal ...
Posted by Michael Wonder on 02 Aug 2022
Characteristics of key patents covering recent FDA approved drugs
1 August 2022 - New drugs are protected by patents that block generic competition and allow manufacturers to charge high prices. ...